Prevalence of Nonalcoholic Steatohepatitis Among Patients with Resectable Intrahepatic Cholangiocarcinoma
- 296 Downloads
Background and Aims
The objective of this report was to determine the prevalence of underlying nonalcoholic steatohepatitis in resectable intrahepatic cholangiocarcinoma.
Demographics, comorbidities, clinicopathologic characteristics, surgical treatments, and outcomes from patients who underwent resection of intrahepatic cholangiocarcinoma at one of eight hepatobiliary centers between 1991 and 2011 were reviewed.
Of 181 patients who underwent resection for intrahepatic cholangiocarcinoma, 31 (17.1 %) had underlying nonalcoholic steatohepatitis. Patients with nonalcoholic steatohepatitis were more likely obese (median body mass index, 30.0 vs. 26.0 kg/m2, p < 0.001) and had higher rates of diabetes mellitus (38.7 vs. 22.0 %, p = 0.05) and the metabolic syndrome (22.6 vs. 10.0 %, p = 0.05) compared with those without nonalcoholic steatohepatitis. Presence and severity of hepatic steatosis, lobular inflammation, and hepatocyte ballooning were more common among nonalcoholic steatohepatitis patients (all p < 0.001). Macrovascular (35.5 vs. 11.3 %, p = 0.01) and any vascular (48.4 vs. 26.7 %, p = 0.02) tumor invasion were more common among patients with nonalcoholic steatohepatitis. There were no differences in recurrence-free (median, 17.0 versus 19.4 months, p = 0.42) or overall (median, 31.5 versus 36.3 months, p = 0.97) survival after surgical resection between patients with and without nonalcoholic steatohepatitis.
Nonalcoholic steatohepatitis affects up to 20 % of patients with resectable intrahepatic cholangiocarcinoma.
KeywordsNonalcoholic fatty liver disease Nonalcoholic steatohepatitis Intrahepatic cholangiocarcinoma Nonalcoholic fatty liver disease activity score
Body mass index
American Joint Committee on Cancer
Nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease activity score
- 2.Pascale A, Pais R, Ratziu V. An overview of nonalcoholic steatohepatitis: past, present, and future directions. J Gastrointest Liver Dis 2010;19:415–23.Google Scholar
- 12.SEER Cancer Statistics Review, 1975–2000. SEER incidence and US mortality rates and trends for the top 15 cancer sites by race/ethnicity. http://seer.cancer.gov/csr/1975_2009_pops09/results_merged/topic_topfifteen.pdf
- 13.SEER Cancer Statistics Review, 1975–2000. CSR sections—liver and bile duct. http://seer.cancer.gov/csr/1975_2009_pops2009/results_merged/sect_14_liver_bile.pdf
- 26.Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–5.PubMedCrossRefGoogle Scholar
- 33.Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD—clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009;49:809–20.PubMedCrossRefGoogle Scholar
- 34.Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005–23.PubMedCrossRefGoogle Scholar
- 40.Reddy SK, Marsh JW, Varley PR, Mock BK, Chopra KB, et al (2012) Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case–control study. Hepatology. doi: 10/1002/hep.25935